Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies

Publications

Supp Table 5 from Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies

Khan AO. et al, (2023)

Supp Table 6 from Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies

Khan AO. et al, (2023)

Supp Table 6 from Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies

Khan AO. et al, (2023)

Supp Table 7 from Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies

Khan AO. et al, (2023)

Supp Table 7 from Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies

Khan AO. et al, (2023)

Supplementary Information from Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies

Khan AO. et al, (2023)

Supplementary Information from Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies

Khan AO. et al, (2023)

Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results From CheckMate 238.

Larkin J. et al, (2023), Clinical cancer research : an official journal of the American Association for Cancer Research

From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit.

Lythgoe MP. et al, (2023), Lancet Oncol, 24, e150 - e160

Is it still worth pursuing the repurposing of metformin as a cancer therapeutic?

Lord SR. and Harris AL., (2023), Br J Cancer, 128, 958 - 966

Data from A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer

Oza AM. et al, (2023)

Data from A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer

Oza AM. et al, (2023)

Data from The Oxford Classic Links Epithelial-to-Mesenchymal Transition to Immunosuppression in Poor Prognosis Ovarian Cancers

Hu Z. et al, (2023)

Data from The Oxford Classic Links Epithelial-to-Mesenchymal Transition to Immunosuppression in Poor Prognosis Ovarian Cancers

Hu Z. et al, (2023)

Data from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface

Cheng VWT. et al, (2023)

Data from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface

Cheng VWT. et al, (2023)

Supplementary Data from A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer

Oza AM. et al, (2023)

Supplementary Data from A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer

Oza AM. et al, (2023)

Supplementary Data from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface

Cheng VWT. et al, (2023)

Supplementary Data from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface

Cheng VWT. et al, (2023)